Wen-Jie Fang, Xin-Ying Zhang, Bo Yang, Shu-Jing Sui, Min Chen, Wei-Hua Pan, Wan-Qing Liao, Ming Zhong, Qing-Cai Wang
{"title":"中药汤剂辅助治疗萎缩性胃炎:系统综述和荟萃分析。","authors":"Wen-Jie Fang, Xin-Ying Zhang, Bo Yang, Shu-Jing Sui, Min Chen, Wei-Hua Pan, Wan-Qing Liao, Ming Zhong, Qing-Cai Wang","doi":"10.21010/ajtcam.v14i4.33","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Chinese herbal decoction (CHD) has been extensively used in the treatment of atrophic gastritis (AG) in China and other Far Eastern countries. We conducted a systematic review and meta-analysis to estimate the efficacy and safety of CHD in AG.</p><p><strong>Materials and methods: </strong>Pubmed, Embase, Cochrane central register of controlled trials (central), VIP, China National Knowledge Infrastructure, Sinomed, Wanfang data were searched (up to December 2015). Randomized controlled trials recruiting patients with AG comparing CHD (alone or with western medicine (WM)) with WM were eligible. Dichotomous data were pooled to obtain relative risk (RR), with a 95% confidence interval (CI).</p><p><strong>Results: </strong>Forty-two articles including 3,874 patients were identified. CHD, used alone or with WM, had beneficial effect over WM in the improvement of clinical manifestations (RR=1.28; 95% CI 1.22-1.34) and pathological change (RR=1.42; 95% CI 1.30-1.54) for AG patients. However, the <i>H. pylori</i> eradication effect of CHD was not supported by the existing clinical evidence, because of the significant study heterogeneity (I<sup>2</sup>>50%) and inconsistency between the primary results and sensitivity analysis.</p><p><strong>Conclusions: </strong>CHD, if prescribed as a complementary therapy to WM, may improve the clinical manifestations and pathological change for AG patients. But its monotherapy for <i>H. pylori</i> eradication is not supported by enough clinical evidence.</p>","PeriodicalId":7845,"journal":{"name":"African journal of traditional, complementary, and alternative medicines : AJTCAM","volume":"14 4","pages":"297-319"},"PeriodicalIF":0.0000,"publicationDate":"2017-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21010/ajtcam.v14i4.33","citationCount":"6","resultStr":"{\"title\":\"CHINESE HERBAL DECOCTION AS A COMPLEMENTARY THERAPY FOR ATROPHIC GASTRITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS.\",\"authors\":\"Wen-Jie Fang, Xin-Ying Zhang, Bo Yang, Shu-Jing Sui, Min Chen, Wei-Hua Pan, Wan-Qing Liao, Ming Zhong, Qing-Cai Wang\",\"doi\":\"10.21010/ajtcam.v14i4.33\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Chinese herbal decoction (CHD) has been extensively used in the treatment of atrophic gastritis (AG) in China and other Far Eastern countries. We conducted a systematic review and meta-analysis to estimate the efficacy and safety of CHD in AG.</p><p><strong>Materials and methods: </strong>Pubmed, Embase, Cochrane central register of controlled trials (central), VIP, China National Knowledge Infrastructure, Sinomed, Wanfang data were searched (up to December 2015). Randomized controlled trials recruiting patients with AG comparing CHD (alone or with western medicine (WM)) with WM were eligible. Dichotomous data were pooled to obtain relative risk (RR), with a 95% confidence interval (CI).</p><p><strong>Results: </strong>Forty-two articles including 3,874 patients were identified. CHD, used alone or with WM, had beneficial effect over WM in the improvement of clinical manifestations (RR=1.28; 95% CI 1.22-1.34) and pathological change (RR=1.42; 95% CI 1.30-1.54) for AG patients. However, the <i>H. pylori</i> eradication effect of CHD was not supported by the existing clinical evidence, because of the significant study heterogeneity (I<sup>2</sup>>50%) and inconsistency between the primary results and sensitivity analysis.</p><p><strong>Conclusions: </strong>CHD, if prescribed as a complementary therapy to WM, may improve the clinical manifestations and pathological change for AG patients. But its monotherapy for <i>H. pylori</i> eradication is not supported by enough clinical evidence.</p>\",\"PeriodicalId\":7845,\"journal\":{\"name\":\"African journal of traditional, complementary, and alternative medicines : AJTCAM\",\"volume\":\"14 4\",\"pages\":\"297-319\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-06-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.21010/ajtcam.v14i4.33\",\"citationCount\":\"6\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"African journal of traditional, complementary, and alternative medicines : AJTCAM\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.21010/ajtcam.v14i4.33\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2017/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"African journal of traditional, complementary, and alternative medicines : AJTCAM","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21010/ajtcam.v14i4.33","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 6
摘要
背景:中药汤剂(CHD)在中国和其他远东国家广泛应用于萎缩性胃炎(AG)的治疗。我们进行了一项系统回顾和荟萃分析,以评估冠心病在AG患者中的疗效和安全性。资料和方法:检索Pubmed、Embase、Cochrane中央对照试验库(central)、维普、中国知网、中国医学信息中心、万方等数据(截至2015年12月)。招募agd患者的随机对照试验将冠心病(单独或联合西药)与西药进行比较。将二分类数据合并以获得相对危险度(RR),置信区间为95%。结果:共纳入42篇文献,3874例患者。冠心病单独使用或与WM联合使用在改善临床表现方面均优于WM (RR=1.28;95% CI 1.22-1.34)和病理改变(RR=1.42;95% CI 1.30-1.54)。然而,由于研究存在显著的异质性(I2>50%),且主要结果与敏感性分析不一致,现有的临床证据并不支持幽门螺杆菌根除冠心病的效果。结论:冠心病作为WM的补充治疗可改善AG患者的临床表现和病理改变。但其根除幽门螺杆菌的单一疗法没有足够的临床证据支持。
CHINESE HERBAL DECOCTION AS A COMPLEMENTARY THERAPY FOR ATROPHIC GASTRITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS.
Background: Chinese herbal decoction (CHD) has been extensively used in the treatment of atrophic gastritis (AG) in China and other Far Eastern countries. We conducted a systematic review and meta-analysis to estimate the efficacy and safety of CHD in AG.
Materials and methods: Pubmed, Embase, Cochrane central register of controlled trials (central), VIP, China National Knowledge Infrastructure, Sinomed, Wanfang data were searched (up to December 2015). Randomized controlled trials recruiting patients with AG comparing CHD (alone or with western medicine (WM)) with WM were eligible. Dichotomous data were pooled to obtain relative risk (RR), with a 95% confidence interval (CI).
Results: Forty-two articles including 3,874 patients were identified. CHD, used alone or with WM, had beneficial effect over WM in the improvement of clinical manifestations (RR=1.28; 95% CI 1.22-1.34) and pathological change (RR=1.42; 95% CI 1.30-1.54) for AG patients. However, the H. pylori eradication effect of CHD was not supported by the existing clinical evidence, because of the significant study heterogeneity (I2>50%) and inconsistency between the primary results and sensitivity analysis.
Conclusions: CHD, if prescribed as a complementary therapy to WM, may improve the clinical manifestations and pathological change for AG patients. But its monotherapy for H. pylori eradication is not supported by enough clinical evidence.